Publication | Open Access

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells

Histone ModificationsChromatinOncologyMedicineEpigenetic ChangeCancer GrowthEpigenetic TherapyAnti-cancer Agent3-Deazaneplanocin APharmacologyCell BiologyEpigeneticsLung CancerHistone Methyltransferase Ezh2